The ENDO Trial and the unfortunate termination....So what actiually happened there?
I was told that Mitomycin was NOT a reasonable option as the SOC ( standard of care ) and therefore enrolment was near impossible...I bought that explanation...
But now at the most formal ADCOMM prceedings we're told that the ENDO Trial failed and enrolment was low because Mitomycin supplies were low and not adequate to run the trial.
Speaking of low supply...why are bladder cancer patients being offered 1/3 the suggested dosage of BCG due to various supply issues ( now lasting 2 years or so ) and this fact not discussed by the experts at ADCOMM?
As mentioned this is the THIRD time in the last 5 YEARS that Bioniche or Telesta has had a major sell-off in the middle of tax loss season....what are the odds of this timing? Too bad for the nervous nellies ; - )